Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Stock Down 5.1 %

Shares of NASDAQ EVGN opened at $1.41 on Monday. The business has a 50-day moving average price of $1.57 and a 200 day moving average price of $2.02. Evogene has a 52-week low of $1.20 and a 52-week high of $9.28. The stock has a market cap of $7.54 million, a PE ratio of -0.31 and a beta of 1.28.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.78. The firm had revenue of $1.61 million during the quarter, compared to the consensus estimate of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same quarter in the previous year, the company posted ($1.30) EPS.

Institutional Trading of Evogene

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned 0.30% of Evogene as of its most recent SEC filing. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.